Immunosuppressants - Iran

Iran

The Immunosuppressants market in Iran is expected to witness a significant growth in revenue, projected to reach US$272.70m in 2024.
Furthermore, it is anticipated that the market will demonstrate a robust annual growth rate (CAGR 2024-2029) of 14.52%, ultimately leading to a substantial market volume of US$537.20m by 2029.
When compared globally, United States is forecasted to generate the highest revenue in this market, amounting to US$35,470.00m in 2024.
Iran's immunosuppressant market is experiencing a surge in demand due to the increasing prevalence of organ transplants in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Iran has been steadily increasing over the years.

Customer preferences: Iran has a high prevalence of autoimmune diseases, leading to a higher demand for immunosuppressants. Additionally, the country has a growing elderly population, who are more susceptible to diseases that require immunosuppressants.

Trends in the market: There has been a shift towards the use of generic immunosuppressants in Iran due to their lower cost compared to branded drugs. This has led to increased competition among manufacturers of generic drugs. Furthermore, the Iranian government has been promoting the use of domestically produced drugs, leading to a rise in the production of immunosuppressants in the country.

Local special circumstances: Iran has been facing economic sanctions, which have led to a shortage of foreign currency and a decline in the value of the Iranian rial. This has made it difficult for the country to import drugs, leading to an increase in the production of drugs domestically. The government has also implemented policies to support local drug manufacturers, leading to an increase in the production of immunosuppressants in the country.

Underlying macroeconomic factors: The Iranian pharmaceutical market is expected to grow in the coming years due to an increase in healthcare spending and a growing population. Additionally, the government has been investing in the healthcare sector, leading to an increase in the number of hospitals and clinics in the country. However, economic sanctions and political instability may hinder the growth of the market in the long run.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.